FDA Proposes Class I Status for Seven Device Accessories: What the 2026 List Means

On 17 August 2026, the United States Food and Drug Administration published a proposed rule that could quietly remove a regulatory burden from seven kinds of medical device accessories. The notice proposes to classify these accessories as Class I and distinct from the parent devices they support, which would make each of them exempt from premarket notification, the pathway most people know as the 510(k). For any company that makes blood pressure tubing, pacemaker cables, ECMO brackets, defibrillator chargers, catheter plugs, surgical smoke sleeves or battery chargers for powered surgical tools, this is a change worth reading carefully.

The document is short, only five pages, but the reasoning behind it decides who benefits and who does not. FDA is not saying that accessories are low risk by default. It is saying that for this specific list, general controls alone are enough to give a reasonable assurance of safety and effectiveness once the accessory is looked at on its own rather than through the lens of a higher-risk parent device. That distinction is the whole story, and it is where most summaries stop too early.

This article explains exactly what FDA proposed, lists the seven accessory types with their product codes, and unpacks the design-control catch that determines eligibility. It also translates the change for Canadian device makers who export to the United States or hold Health Canada licences, and it walks through how to file a comment before the deadline. The goal is a decision-ready briefing, not a headline.

Executive summary

FDA has issued a periodic proposal under the FDA Reauthorization Act of 2017 to classify a defined list of existing device accessories into Class I, distinct from their parent devices. Class I status generally means the accessory is exempt from 510(k) premarket notification, subject to the usual limitations of exemption. The proposal covers seven accessory types across cardiovascular, general and plastic surgery, and general hospital device categories. Comments are open until 16 October 2026, and the list is not final until FDA publishes a final action after reviewing comments.

What FDA proposed, in plain terms

What it is: a proposed rule, formally a notification and request for comments, that identifies seven medical device accessories FDA believes should be classified as Class I and treated as distinct from the parent devices with which they are used. What it means: if the list is finalized as proposed, each accessory would get its own Class I classification regulation and would be exempt from 510(k) premarket notification. What to do: manufacturers of these accessories should confirm their product codes, decide whether the proposal fits their device, and file a comment if they support, oppose, or want to add to the list.

The mechanism is called distinct classification. Normally an accessory can inherit a higher regulatory class because it was cleared or approved as part of a submission for its parent device or system. FDA is proposing to look at each listed accessory on its own risk profile. When general controls alone are enough for that accessory, it does not need to carry the parent device's premarket burden. FDA first asked the public which accessories to consider in a request posted on its website on 5 December 2025, and this proposal is the follow-up to that request.

The seven accessories on the proposed list

FDA proposed the following seven accessory types for distinct classification into Class I. Each currently has marketing authorization as part of a premarket submission for another device. The product codes matter, because your comment carries more weight when it names the exact product code and classification regulation.

FDA also noted that it received suggestions to classify reprocessing aids and percutaneous catheterization accessories, but those suggestions did not identify product codes or classification regulations, so they are not on the proposed list. That gap is an opening for anyone who wants those accessories considered: a comment that names the product code and classification regulation is far more useful to FDA than a general request.

Why Class I matters: the 510(k) exemption and the design-control catch

Why it matters: Class I is the lowest of the three United States device classes, and most Class I devices are exempt from 510(k) premarket notification. That removes a submission, a review timeline and a user fee from the path to market. But there is a catch that decides eligibility, and it is the single most important sentence in the proposal for a quality professional to understand.

Under the Quality Management System Regulation in 21 CFR part 820, requirements for design and development controls generally do not apply to Class I devices, except for those identified in 21 CFR 820.10(c)(2) and those automated with computer software. FDA used exactly this rule to build the list. If an accessory is not software-automated but would need design controls to give a reasonable assurance of safety and effectiveness, FDA does not consider it eligible for distinct classification through this process. In other words, the absence of a design-control obligation is not a reward for being Class I. It is the entry requirement for the list. For the wider shift in how FDA now expects that quality system to be built, see our guide to the FDA QMSR and ISO 13485 transition.

There is a second qualifier that firms miss. Class I exemptions are subject to the limitations of exemption in 21 CFR 870.9, 876.9 or 878.9. Those limitations claw back the exemption when a device exceeds the boundaries of the generic type, for example through a new intended use or a new technological characteristic that raises different safety questions. An accessory that drifts beyond the classification description does not get to keep the exemption. This is why the exact device-type identification in the proposed rule matters so much.

The eligibility test FDA applied

What it is: a three-part screen that FDA uses to decide whether an accessory can be classified into Class I distinct from its parent. What to do: run your own accessory through the same three questions before you rely on, or object to, the proposal.

FDA considers an accessory eligible for distinct Class I classification if it meets all three of the following conditions, taken from section 513(f)(6)(A) of the Act and the agency's stated factors:

• It is not for use in supporting or sustaining human life, and is not of substantial importance in preventing impairment to human health, as those terms are used in 21 CFR 860.3.
• It does not present a potential unreasonable risk of illness or injury.
• General controls alone would be sufficient to provide a reasonable assurance of safety and effectiveness.

There is also an exclusion that catches many accessories. Device-specific accessories, which are designed for a specific parent device based on unique dimensions, geometry or deployment, are not generally eligible through this process. For these, design specifications are critical to how the accessory supports the parent, so design and development controls remain an important element of safety and effectiveness. FDA first set out this rationale for device-specific orthopedic instruments in an August 2018 proposal and adopted it in an April 2019 final action, and it applies the same principle here.

What this means for Canadian device makers and exporters

Why it matters: many Canadian device companies sell accessories into the United States, and a 510(k) exemption changes the cost and timeline of that market. What to do: map each accessory you export to a United States product code, check whether it is on the proposed list, and confirm how your Health Canada classification lines up.

The distinct-classification concept is a United States construct created by FDARA. Canada does not classify accessories by inheritance in the same way. Under the Medical Devices Regulations (SOR/98-282), Health Canada classifies each device, including an accessory that meets the definition of a medical device, into Class I, II, III or IV using the risk-based classification rules in the Regulations. Class I devices are the lowest risk and are handled through a Medical Device Establishment Licence rather than a Medical Device Licence, while Classes II, III and IV require a Medical Device Licence. A device that is Class I in the United States is not automatically Class I in Canada, and the reverse is also true, so each market needs its own classification analysis. Device firms should also track how Health Canada's recognized standards list is going continuous.

The practical takeaway for a Canadian exporter is that a United States 510(k) exemption can lower your American regulatory burden without changing anything about your Canadian obligations. Your Health Canada licence, your quality system certification under the Medical Devices Single Audit Program, and your establishment licensing all stay in place. The two regimes move on separate tracks, and a change in one is not a change in the other. This is a common source of confusion when a product manager reads a United States headline and assumes it applies at home.

How to comment before 16 October 2026

What to do: if you want FDA to keep, remove or expand an accessory on the list, file a comment through the federal docket before the deadline. Comments close on 16 October 2026 at 11:59 pm Eastern Time, and FDA has stated that late comments will not be considered.

A useful comment does three things. First, it identifies the accessory by product code and classification regulation, because FDA has said that product-code-level detail is what allows it to identify and potentially classify an accessory. Second, it explains why general controls alone are, or are not, sufficient for that accessory. If you support Class I status, make the safety case for general controls. If you oppose it, explain why premarket review through a 510(k) or premarket approval is necessary. Third, it stays inside the eligibility factors FDA actually applies, rather than arguing policy in the abstract.

Comments go to Docket No. FDA-2025-N-6224 at the federal eRulemaking portal. Confidential business information, such as a manufacturing process, should be submitted only as a written paper submission with the confidential material clearly marked, because electronic comments are posted to the public docket unchanged.

Compliance checklist

Use this checklist to decide whether the proposal affects your accessory and what to do next.

• Identify the exact product code and classification regulation for each accessory you manufacture or import.
• Check whether the product code appears in the proposed list of seven accessories.
• Confirm the accessory is not software-automated and does not require design controls under 21 CFR 820.10(c)(2).
• Confirm the accessory is not a device-specific accessory whose dimensions or geometry are critical to a single parent device.
• If the list is finalized, verify your accessory still fits the device-type identification and does not exceed the limitations of exemption in 21 CFR 870.9, 876.9 or 878.9.
• Maintain your quality system under 21 CFR part 820, including registration, listing, labelling and complaint handling, regardless of the 510(k) exemption.
• Map your United States classification to your Health Canada classification and confirm your Canadian licences are unaffected.
• Decide whether to comment, and draft a comment that names the product code and makes the general-controls case, before 16 October 2026.

Common mistakes

Treating a 510(k) exemption as a quality-system exemption

The most frequent error is assuming that Class I status removes the obligation to work under 21 CFR part 820. It does not. Design controls may not apply, but the rest of the quality system, including document control, complaint handling, corrective and preventive action and good manufacturing practices, still governs the accessory. A corrective and preventive action programme that lapses because a team believed the product was unregulated is a classic finding. Our guide on why CAPA keeps failing shows how to keep that programme audit-ready.

Assuming the exemption is automatic and permanent

The list is a proposal until FDA publishes a final action. Nothing changes on 17 August 2026 for a manufacturer's obligations. And even after a final classification, the limitations of exemption can pull a device back into premarket review if its intended use or technology changes. Firms that treat the exemption as unconditional set themselves up for a misbranding problem.

Confusing United States and Canadian classification

A device that becomes Class I and 510(k)-exempt in the United States keeps its own separate classification in Canada under SOR/98-282. Assuming the two align leads companies to under-prepare a Health Canada submission or to misjudge which licence they need.

Filing a vague comment

A comment that argues in generalities, without a product code or a classification regulation, gives FDA nothing to act on. The agency said as much when it declined to add reprocessing aids and percutaneous catheterization accessories, because those suggestions lacked product codes.

Frequently asked questions

Does this proposal remove all regulatory requirements for the seven accessories?

No. It would remove the 510(k) premarket notification requirement by classifying the accessories into Class I. General controls remain, including establishment registration, device listing, labelling requirements, adverse event reporting and good manufacturing practices under the Quality Management System Regulation. The change reduces premarket burden, not the ongoing quality obligation.

When does the change take effect?

It has not taken effect. The document published on 17 August 2026 is a proposal with a comment period that closes on 16 October 2026. FDA will consider comments and then publish a separate final action that distinctly classifies suitable accessories into Class I, if any. Only that final action changes the classification.

What is the legal authority for distinct classification of accessories?

Section 513(f)(6)(D)(i) of the Federal Food, Drug, and Cosmetic Act, added by section 707 of the FDA Reauthorization Act of 2017, directs FDA to periodically propose accessories that may be suitable for distinct classification into Class I and to seek public comment. This proposal is one of those periodic proposals.

Why are device-specific accessories excluded?

Device-specific accessories are built for a particular parent device based on unique dimensions, geometry or deployment, so their design specifications are critical to safe use. Because design and development controls are important for those accessories, general controls alone are not sufficient, and they do not qualify for distinct Class I classification through this process.

Does a United States Class I classification apply to my Health Canada licence?

No. Health Canada classifies medical devices, including accessories, on their own risk under the Medical Devices Regulations, independent of the United States classification. A change in United States status does not change your Canadian class, your Medical Device Licence or your establishment licensing. Each market needs its own analysis.

How do I make my comment count?

Name the accessory by product code and classification regulation, explain whether general controls alone are sufficient, and stay within FDA's stated eligibility factors. File through Docket No. FDA-2025-N-6224 before 16 October 2026, and submit any confidential business information as a marked paper submission rather than in the public electronic docket.

How MFLRC can help

Classification decisions look simple until a product straddles two device types or a quality system has to prove it never needed design controls in the first place. MF License and Regulatory Consultants works with device manufacturers and importers on exactly these questions. We map accessories to the correct product codes, test them against the distinct-classification eligibility factors, and draft comments that name the product code and make the general-controls case in language FDA can act on. We also help teams prepare for and respond to inspection findings, including how to respond to an FDA Form 483 or Health Canada observation.

Our team also keeps your quality system defensible on both sides of the border. That includes gap assessments against 21 CFR part 820 and ISO 13485, standard operating procedure development, corrective and preventive action support, inspection-readiness and mock audits, and Health Canada licensing and Medical Device Single Audit Program readiness. If you export accessories to the United States, we align your American classification strategy with your Canadian Medical Device Establishment Licence and Medical Device Licence obligations so the two regimes stay consistent. Explore our quality control services, audit services and regulatory affairs, licensing and import/export support.

Whether you want to confirm that an accessory qualifies for the proposed list, prepare a comment before the deadline, or make sure a 510(k) exemption does not become a quality-system blind spot, we can help you move with confidence.

Conclusion

FDA's proposed Class I list for seven device accessories is a small notice with a clear logic. General controls alone are enough for these accessories once they are viewed on their own risk, so they can shed the 510(k) that came with their parent devices. The value is real, a lower premarket burden, but it comes with conditions: no design controls needed, no device-specific dependency, and no drift beyond the classification description. Manufacturers who understand the eligibility test can act on the proposal with precision, comment where it matters, and keep their quality systems intact. Canadian exporters should treat the change as United States-only and keep their Health Canada obligations firmly in view. The comment window closes on 16 October 2026, and a well-targeted comment is the cheapest way to shape the final list.

Sources and references

• US FDA, Medical Devices; Classification of Accessories Distinct From Other Devices; Proposed List of Accessories Suitable for Class I (91 FR 53205, 17 August 2026)
• Regulations.gov docket FDA-2025-N-6224 (submit comments)
• US FDA, Medical Device Accessories overview
• 21 CFR part 820, Quality Management System Regulation (design controls at 820.10)
• Health Canada, Medical Devices Regulations (SOR/98-282)